Folic acid may slow chronic kidney disease progression
People with chronic kidney disease (CKD) often have elevated levels of homocysteine, an inflammatory factor linked to folate deficiency. In this study, 15,104 participants with moderate or chronic kidney disease continued to take enalapril to slow its progress, with or without 800 mcg of folic acid per day. Over an average 4.4 years of follow-up, those taking folic acid were 21 percent less likely to see the condition progress compared to those who took enalapril alone. Among those who began the study with CKD, 3.3 percent of those taking folic acid saw the condition progress compared to 6.8 percent for enalapril alone. The greatest folic acid benefit appeared in those who started the study with mild to moderate CKD, where chances of the condition progressing were reduced by 56 and 44 percent, respectively.

Reference: JAMA Internal Medicine; 2016, Vol. 176, No. 10, 1443-50.
Previous Next Back to Top
More Related Articles